This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2011
  • /
  • 02
  • /
  • MiStent (Micell Technologies) enters Phase III tri...
Drug news

MiStent (Micell Technologies) enters Phase III trial for CAD

Read time: 1 mins
Last updated:19th Feb 2011
Published:19th Feb 2011
Source: Pharmawand
Micell Technologies,Inc. announced it has enrolled the first patient in the DESSOLVE II (DES with Sirolimus and a bioabsorbable pOLymer for the treatment of patients with de noVo lesions in the native coronary arteries) clinical trial. This clinical investigation is being conducted to support CE Mark approval of the company's MiStent Drug-Eluting Coronary Stent System and compares the MiCell MiStent with the Medtronic Inc. Endeavour drug eluting stent.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.